The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction
Clinical Cardiology · 2024
DOI: 10.1002/clc.24234 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Robert A Kloner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Huntington Medical Research Institutes, Pasadena, California, USA. Hauptthemen laut MEDLINE: Erectile Dysfunction, Myocardial Infarction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Background
Tadalafil is a long‐acting phosphodiesterase‐5 inhibitor (PDE‐5i) indicated for erectile dysfunction (ED). Hypothesis Our hypothesis was that tadalafil will reduce the risk of major adverse cardiovascular events (MACE: composite of cardiovascular death, myocardial infarction, coronary revascularization, unstable angina, heart failure, stroke) and all‐cause death in men with ED.
Methods
A retrospective observational cohort study was conducted in a large US commercial insurance claims database in men with a diagnosis of ED without prior MACE within 1 year. The exposed group ( n = 8156) had ≥1 claim for tadalafil; the unexposed group ( n = 21 012) had no claims for any PDE‐5i.
Results
Primary outcome was MACE; secondary outcome was all‐cause death. Groups were matched for cardiovascular risk factors, including preventive therapy. Over a mean follow‐up of 37 months for the exposed group and 29 months for the unexposed group, adjusted rates of MACE were 19% lower in men exposed to tadalafil versus those unexposed to any PDE‐5i (hazard ratio [HR] = 0.81; 95% confidence intervals [CI] = 0.70−0.94; p = .007). Tadalafil exposure was associated with lower adjusted rates of coronary revascularization (HR = 0.69; 95% CI = 0.52−0.90; p = .006); unstable angina (HR = 0.55; 95% CI = 0.37−0.81; p = .003); and cardiovascular‐related mortality (HR = 0.45; CI = 0.22−0.93; p = .032). Overall mortality rate was 44% lower in men exposed to tadalafil (HR = 0.56; CI = 0.43−0.74; p < .001). Men in the highest quartile of tadalafil exposure had the lowest rates of MACE (HR: 0.40; 95% CI: 0.28−0.58; p < .001) compared to lowest exposure quartile.
Conclusion
In men with ED, exposure to tadalafil was associated with significant and clinically meaningful lower rates of MACE and overall mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huntington Medical Research Institutes, Pasadena, California, USA.
- Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
- Elevance Health Inc., Indianapolis, Indiana, USA.
- Carelon Research Inc., Wilmington, Delaware, USA.
- Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Förderung
- Sanofi
Zitieren
APA
Kloner, R. A., Stanek, E., Desai, K., Crowe, C. L., Paige Ball, K., Haynes, A., & Rosen, R. C. (2024). The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction. Clinical Cardiology. https://doi.org/10.1002/clc.24234
Vancouver
Kloner RA, Stanek E, Desai K, Crowe CL, Paige Ball K, Haynes A, et al. The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction. Clinical Cardiology. 2024. doi:10.1002/clc.24234
BibTeX
@article{Kloner2024,
author = {Kloner, Robert A and Stanek, Eric and Desai, Karishma and Crowe, Christopher L and Paige Ball, Kathryn and Haynes, Aaron and Rosen, Raymond C},
title = {The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24234}
}
EUVIMED